ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Aug 22, 2012
Dividend Growth Gem Medtronic Posts a Decent First Quarter
Medical heart-rhythm device maker Medtronic posted solid first-quarter results. The company remains an attractive dividend growth idea.
Jul 19, 2012
Our Outlook for the Market
President of Equity Research & ETF Analysis, Brian Nelson offers insight into Valuentum's outlook for the market.
Jun 22, 2012
Dividend Growth Favorite Medtronic Raises Dividend 7%
Medical device-maker Medtronic (MDT) announced that it will increase its quarterly dividend 7% to $0.26 per share. This translates to a pay out of $1.04 per year, or an annual yield of 2.8% at current levels.
Jun 13, 2012
Johnson and Johnson’s Deal for Synthes Closes; Healthcare Spending Will Grow
We take a look at some recent developments in the healthcare industry.
May 22, 2012
Medtronic Gaining Share in the US Drug-Eluting Stent Market
Medtronic posted strong fiscal fourth-quarter results and offered a solid outlook for its fiscal 2013. We're big fans of the medical device maker's dividend-growth profile and expect the company to continue to return cash to shareholders.
Tandem Diabetes Care: An Emerging Leader in Diabetes Technology
Image Source: Tandem Investor PresentationOver the past year or so, Tandem Diabetes Care has gone from jockeying for position in the domestic insulin pump market to a global leader in diabetes care technology. Significant growth catalysts remain in place, and the company expects to soon begin realizing meaningful efficiencies of scale as robust top-line growth continues.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.